Open AccessSorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines
Author(s) -
Matthias Riedel,
Nina Struve,
Justus Müller-Goebel,
Sabrina Köcher,
Cordula Petersen,
Ekkehard Dikomey,
Kai Rothkamm,
Malte Kriegs
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.11328
Subject(s) - sorafenib , glioblastoma , cancer research , medicine , cell growth , cell culture , oncology , chemosensitivity assay , cell , biology , tumor cells , genetics , hepatocellular carcinoma
Glioblastomas (GBM) are the most common malignant type of primary brain tumor. GBM are intensively treated with surgery and combined radiochemotherapy using X-irradiation and temozolomide (TMZ) but they are still associated with an extremely poor prognosis, urging for the development of new treatment strategies. To improve the outcome of GBM patients, the small molecule multi-kinase inhibitor sorafenib has moved into focus of recent research. Sorafenib has already been shown to enhance the radio- and radiochemosensitivity of other tumor entities. Whether sorafenib is also able to sensitize GBM cells to radio- and chemotherapy is still an unsolved question which we have addressed in this study.